Company news

JW (Cayman) Therapeutics Co. Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 4, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

2026 Interim report

September 24, 2026

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

October 31, 2025

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

June 4, 2025

JW Therapeutics - Receipt of Breakthrough Therapy Designation for Carteyva in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

January 13, 2025

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

July 4, 2022

JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma

March 31, 2022

JW (Cayman) Therapeutics: Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

September 6, 2021

Change of company secretary, authorized representative and process agent

July 30, 2021

JW (Cayman) Therapeutics: Proposals for general mandates to issue shares and repurchase shares and re-election of retiring directors and re-appointment of auditor and notice of annual general meeting

April 23, 2021

Voluntary announcement - inclusion of the shares of the company in the hong kong stock connect list under the shenzhen-hong kong stock connect

March 15, 2021

Decks

The 5 newest of 7 decks. Every deck is listed under its year.